Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics develops and commercializes therapies for cardiometabolic and rare/orphan diseases, with a commercial focus on oral, once-daily, non-statin LDL-C treatments for patients at risk for cardiovascular disease. Company news commonly covers NEXLETOL bempedoic acid data, CLEAR Outcomes analyses, dyslipidemia guideline developments, financial results, business updates, and material agreements.
Esperion's news also reflects portfolio expansion through its completed acquisition of Corstasis Therapeutics and Enbumyst bumetanide nasal spray, an FDA-approved loop diuretic for edema associated with congestive heart failure and hepatic or renal disease in adults. Additional recurring topics include ACLY biology, product commercialization, pipeline work in Primary Sclerosing Cholangitis and renal diseases, and governance or capital-structure matters.
Esperion granted 62,300 RSUs to 16 new employees under the 2017 Inducement Equity Incentive Plan. The RSUs will vest over time based on employment. Esperion focuses on developing medicines for cardiovascular diseases, striving to improve patient outcomes. For more info, visit esperion.com.
Esperion reported impressive Q1 2024 financial results with total revenue growing 467% Y/Y to $137.7 million and U.S. net product revenue increasing 46% Y/Y to $24.8 million. They received FDA approval for label expansions of NEXLETOL and NEXLIZET, making them the first non-statins to prevent heart attacks. Positive CHMP opinion expected from European Commission in Q2 2024. Collaboration revenue surged by 1,448% Y/Y. The company's cash balance is strong at $226.6 million. Financial outlook remains positive for 2024 with operating expenses projected at $225-245 million.
Esperion (NASDAQ: ESPR) will participate in investor events in May, including JMP Securities’ Life Sciences Conference, Bank of America Securities’ Health Care Conference, and H.C. Wainwright’s BioConnect Investor Conference. Esperion focuses on developing medicines for cardiovascular and cardiometabolic diseases, aiming to improve outcomes for patients with high cholesterol.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.